Biodesix, Inc.
BDSX
$8.44
$0.303.62%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 80.17M | 76.56M | 74.46M | 71.32M | 65.56M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 80.17M | 76.56M | 74.46M | 71.32M | 65.56M |
| Cost of Revenue | 16.18M | 16.26M | 16.10M | 15.57M | 14.61M |
| Gross Profit | 63.99M | 60.30M | 58.36M | 55.75M | 50.96M |
| SG&A Expenses | 84.79M | 83.09M | 80.34M | 80.45M | 76.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 112.52M | 110.45M | 106.83M | 105.58M | 100.12M |
| Operating Income | -32.35M | -33.89M | -32.37M | -34.26M | -34.56M |
| Income Before Tax | -39.54M | -41.08M | -40.42M | -42.93M | -43.82M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.54 | -41.08 | -40.42 | -42.93 | -43.82 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.54M | -41.08M | -40.42M | -42.93M | -43.82M |
| EBIT | -32.35M | -33.89M | -32.37M | -34.26M | -34.56M |
| EBITDA | -26.61M | -28.08M | -26.58M | -28.49M | -29.26M |
| EPS Basic | -5.37 | -5.61 | -5.74 | -7.03 | -7.88 |
| Normalized Basic EPS | -3.34 | -3.49 | -3.54 | -4.35 | -4.88 |
| EPS Diluted | -5.37 | -5.61 | -5.74 | -7.03 | -7.88 |
| Normalized Diluted EPS | -3.34 | -3.49 | -3.54 | -4.35 | -4.88 |
| Average Basic Shares Outstanding | 29.49M | 29.31M | 28.33M | 25.86M | 23.15M |
| Average Diluted Shares Outstanding | 29.49M | 29.31M | 28.33M | 25.86M | 23.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |